



TML: CS: BSE/NSE CORR: 2022-23

18th May, 2022

The Manager
Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051

Sub: Receipt of add on approval for our drug VIRALEX for the treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

Ref: 1. Regulation 30 of the SEBI (LODR) Regulations, 2015
2. BSE Scrip Code: 530199
3. NSE Scrip Code: THEMISMED

Dear Sir/Madam,

We are pleased to announce the add on approval for our drug **VIRALEX®** by the Drug Controller General of India (DCGI) for treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

VIRALEX® (Inosine Pranobex) is an **immunomodulatory** agent with **broad spectrum antiviral** properties. Earlier VIRALEX® was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two *Randomized controlled trials (RCT) in 499 Indian patients.*

VIRALEX® would be available on prescription.


Inosine Pranobex is in clinical use for **>50 years** since its first approval internationally. It is currently marketed in **>70 countries** across the world including many advance countries for the treatment of several viral diseases with established efficacy and safety profile.

VIRALEX® strengthens the immune system through modulation of T-cell proliferation, T-cell function, natural killer cell activity, phagocytosis, and also by modulating certain cytokines, and enhances body's immune response to various viral infections.

Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India
Tel. : 91-22-6760 7080 • **Fax :** 91-22-6760 7070 / 2874 6621
Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.
CIN No.: L24110GJ1969PLC001590 • **Tel / Fax No.:** **Regd. Off. :** 0260 2431447 / 2430219
• **E-mail :** themis@themismedicare.com • **Website :** www.themismedicare.com





NK cells are the first line defense against viral infections. VIRALEX® enhances human NK cell cytotoxicity in two ways by increasing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Based on world wide experience, *the drug offers clinical benefits to the patients and addresses the unmet medical need in management of various viral infections, especially influenza and AVRI.* **VIRALEX®** is manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication is available on prescription in the form of a 500 mg tablet at an affordable price.

Kindly take this on record.

Thanking you,

Yours faithfully,

For Themis Medicare Ltd.



Sangameshwar Iyer
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India

Tel. : 91-22-6760 7080 • **Fax :** 91-22-6760 7070 / 2874 6621

Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.

CIN No.: L24110GJ1969PLC001590 • **Tel / Fax No.:** **Regd. Off. :** 0260 2431447 / 2430219

• **E-mail :** themis@themismedicare.com • **Website :** www.themismedicare.com



PRESS NOTE CONTENT

Mumbai, India; 18 May 2022

Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the add on approval for drug **VIRALEX®** by the Drug Controller General of India (DCGI) for treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

VIRALEX® (Inosine Pranobex) is an **immunomodulatory** agent with **broad spectrum antiviral** properties. Earlier VIRALEX® was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two *Randomized controlled trials (RCT) in 499 Indian patients.*

Inosine Pranobex is in clinical use for **>50 years** since its first approval internationally. It is currently marketed in **>70 countries** across the world including many advance countries for the treatment of several viral diseases with established efficacy and safety profile.

VIRALEX® strengthens the immune system through modulation of T-cell proliferation, T-cell function, natural killer cell activity, phagocytosis, and also by modulating certain cytokines, and enhances body's immune response to various viral infections.

NK cells are the first line defense against viral infections. VIRALEX® enhances human NK cell cytotoxicity in two ways by increasing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Based on world wide experience, *the drug offer clinical benefits to the patients and address the unmet medical need in management of various viral infections, especially influenza and AVRI.*

According to Themis, **VIRALEX®** is manufactured at an **EU-GMP-certified facility** with the highest safety standards and stringent manufacturing protocols in place, and the medication is available on prescription in the form of a 500 mg tablet at an affordable price.

Themis Medicare Limited

Corporate Office: 11/12, Udyog Nagar, S.V. Road, Goregaon (West), Mumbai- 400 104 India
Tel: 91 – 22 – 67607080 • **Fax:** 91 – 22 – 67607070 / 28746621
Regd. Office: Plot No.69-A, G.I.D.C. Industrial Estate, Vapi-396 195, Gujarat
CIN No: L24110GJ1969PLC001590 • **Tel / Fax No:** **Regd. Off:** 0260 2431447 / 2430219
• **E-mail:** themis@themismedicare.com • **Website:** www.themismedicare.com



Speaking at the release, *Dr. Sachin Patel, Managing Director & CEO* of Themis Medicare Ltd. said, “Our endeavor has always been to develop medicines that address unmet medical needs and make healthcare far, far more effective for patient benefits”.

With a strong R&D backup, skilled domestic & export teams, and state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for therapeutic gaps, like **VIRALEX[®]** for treating Viral Infections ... and still counting!

About Themis Medicare Ltd.

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma Company specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug-delivery systems, the Company has evolved into being a formidable player in the complex generics space. It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs – 1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectables portfolio and develop its NDDS presence

Themis Medicare Limited

Corporate Office: 11/12, Udyog Nagar, S.V. Road, Goregaon (West), Mumbai- 400 104 India
Tel: 91 – 22 – 67607080 • **Fax:** 91 – 22 – 67607070 / 28746621
Regd. Office: Plot No.69-A, G.I.D.C. Industrial Estate, Vapi-396 195, Gujarat
CIN No: L24110GJ1969PLC001590 • **Tel / Fax No:** **Regd. Off:** 0260 2431447 / 2430219
• **E-mail:** themis@themismedicare.com • **Website:** www.themismedicare.com